Evidence map›Paper›PMID 40142960›Full record

ReviewPharmaceutics2025

Advances in Materials Science for Precision Melanoma Therapy: Nanotechnology-Enhanced Drug Delivery Systems.

Sivakumar S Moni, Jobran M Moshi, Sabine Matou-Nasri, Shmoukh Alotaibi, Yousef M Hawsawi, Mohamed Eltaib Elmobark, Ahlam Mohammed S Hakami, Mohammed A Jeraiby, Ahmed A Sulayli, Hassan N Moafa

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sivakumar S MoniCollege of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0002-4860-0166
Jobran M MoshiDepartment of Medical Laboratory Technology, College of Nursing and Health Science, Jazan University, Jazan 45142, Saudi Arabia.
Sabine Matou-NasriBlood and Cancer Research Department, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh 11481, Saudi Arabia.ORCID 0000-0003-4372-2903
Shmoukh AlotaibiResearch Center, King Faisal Specialist Hospital and Research Center, Jeddah 23433, Saudi Arabia.
Yousef M HawsawiResearch Center, King Faisal Specialist Hospital and Research Center, Jeddah 23433, Saudi Arabia.ORCID 0000-0003-1901-697X
Mohamed Eltaib ElmobarkCollege of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.
Ahlam Mohammed S HakamiDepartment Obstetrics and Gynecology, Jazan University, Jazan 45142, Saudi Arabia.
Mohammed A JeraibyDepartment of Basic Medical Science, Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0002-5428-9167
Ahmed A SulayliLaboratory Department, Prince Mohammed bin Nasser Hospital, Jazan Health Cluster, Jazan 82734, Saudi Arabia.
Hassan N MoafaDepartment of Public Health, College of Nursing and Health Sciences, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0003-4078-9467

Funding

Deanship ‎of Graduate Studies and Scientific Research, Jazan University, Saudi Arabia ‎GSSRD-24‎
6 · The paper itself

Abstract

Melanoma, a highly aggressive form of skin cancer, poses a major therapeutic challenge due to its metastatic potential, resistance to conventional therapies, and the complexity of the tumor microenvironment (TME). Materials science and nanotechnology advances have led to using nanocarriers such as liposomes, dendrimers, polymeric nanoparticles, and metallic nanoparticles as transformative solutions for precision melanoma therapy. This review summarizes findings from Web of Science, PubMed, EMBASE, Scopus, and Google Scholar and highlights the role of nanotechnology in overcoming melanoma treatment barriers. Nanoparticles facilitate passive and active targeting through mechanisms such as the enhanced permeability and retention (EPR) effect and functionalization with tumor-specific ligands, thereby improving the accuracy of drug delivery and reducing systemic toxicity. Stimuli-responsive systems and multi-stage targeting further improve therapeutic precision and overcome challenges such as poor tumor penetration and drug resistance. Emerging therapeutic platforms combine diagnostic imaging with therapeutic delivery, paving the way for personalized medicine. However, there are still issues with scalability, biocompatibility, and regulatory compliance. This comprehensive review highlights the potential of integrating nanotechnology with advances in genetics and proteomics, scalable, and patient-specific therapies. These interdisciplinary innovations promise to redefine the treatment of melanoma and provide safer, more effective, and more accessible treatments. Continued research is essential to bridge the gap between evidence-based scientific advances and clinical applications.

Indexed as

drug delivery systemsmaterials sciencemelanoma therapynanotechnologypersonalized medicinetargeted delivery systemtumor microenvironment

Identifiers

PMID40142960
PMCPMC11945159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.